Get the Stockscreener App
2.00
3.63%
+0.07
After Hours:
2.02
0.02
+1.00%
Atyr Pharma Inc stock is currently priced at $2.00, with a 24-hour trading volume of 575.47K.
It has seen a +3.63% increased in the last 24 hours and a +25.79% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $1.93 pivot point. If it approaches the $2.01 resistance level, significant changes may occur.
Previous Close:
$1.93
Open:
$1.92
24h Volume:
575.47K
Market Cap:
$138.02M
Revenue:
-
Net Income/Loss:
$-50.39M
P/E Ratio:
-1.626
EPS:
-1.23
Net Cash Flow:
$-37.44M
1W Performance:
+18.34%
1M Performance:
+25.79%
6M Performance:
+75.44%
1Y Performance:
-20.63%
1D Range:
$1.915
$2.02
52W Range:
$1.0801
$2.60
Atyr Pharma Inc Stock (LIFE) Company Profile
Name
Atyr Pharma Inc
Sector
Industry
Phone
858-731-8389
Address
3545 John Hopkins Court, Suite 250, San Diego, CA
Atyr Pharma Inc Stock (LIFE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-12-21 | Initiated | RBC Capital Mkts | Outperform |
| Sep-21-21 | Initiated | Piper Sandler | Overweight |
| May-10-21 | Initiated | Laidlaw | Buy |
| Aug-17-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-04-20 | Initiated | ROTH Capital | Buy |
| Mar-02-20 | Initiated | Oppenheimer | Outperform |
| Feb-14-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-07-17 | Initiated | Piper Jaffray | Overweight |
| Dec-13-16 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-16-15 | Initiated | Citigroup | Neutral |
| Jun-01-15 | Initiated | Citigroup | Buy |
| Jun-01-15 | Initiated | JP Morgan | Overweight |
View All
Atyr Pharma Inc Stock (LIFE) Latest News
Wall Street Breakfast: The Week Ahead
Seeking Alpha
HC Wainwright Reiterates Buy Rating for aTyr Pharma (NASDAQ:LIFE) - Defense World
Defense World
Atyr Pharma (LIFE) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Movies UK
Yahoo Movies UK
aTyr Pharma to Present Poster Describing Efzofitimod's - GlobeNewswire
GlobeNewswire
aTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International Conference
GlobeNewswire Inc.
aTyr Pharma (NASDAQ:LIFE) Given "Buy" Rating at HC Wainwright - MarketBeat
MarketBeat
Atyr Pharma Inc Stock (LIFE) Financials Data
Atyr Pharma Inc (LIFE) Net Income 2024
LIFE net income (TTM) was -$50.39 million for the quarter ending December 31, 2023, a -11.14% decrease year-over-year.
Atyr Pharma Inc (LIFE) Cash Flow 2024
LIFE recorded a free cash flow (TTM) of -$37.44 million for the quarter ending December 31, 2023, a +13.99% increase year-over-year.
Atyr Pharma Inc (LIFE) Earnings per Share 2024
LIFE earnings per share (TTM) was -$0.96 for the quarter ending December 31, 2023, a +40.00% growth year-over-year.
Atyr Pharma Inc Stock (LIFE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Shukla Sanjay | President and CEO |
Dec 12 '23 |
Buy |
1.18 |
12,000 |
14,136 |
106,173 |
| Shukla Sanjay | President and CEO |
Dec 11 '23 |
Buy |
1.17 |
3,000 |
3,510 |
94,173 |
| Shukla Sanjay | President and CEO |
Nov 13 '23 |
Buy |
1.11 |
13,578 |
15,085 |
91,173 |
| Shukla Sanjay | President and CEO |
Nov 10 '23 |
Buy |
1.14 |
1,422 |
1,618 |
77,595 |
| Shukla Sanjay | President and CEO |
Jul 28 '23 |
Buy |
2.01 |
15,000 |
30,224 |
76,173 |
About Atyr Pharma Inc
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of medicines for the treatment of cancer and lung disease in the United States. The company's therapeutic candidate pipeline that includes ATYR1923 candidate, an agonist of the Resokine pathway that is in Phase I clinical trial designed to temper immune engagement in interstitial lung diseases; and ORCA program, a preclinical research stage program that targets immuno-oncology pathway using antibodies to enhance the immune response in tumor settings. It is also developing ATYR1940, a therapeutic candidate based on a protein naturally secreted from muscle for the treatment of facioscapulohumeral muscular dystrophy, limb-girdle muscular dystrophy, and duchenne muscular dystrophy. aTyr Pharma, Inc. was founded in 2005 and is headquartered in San Diego, California.
0.77%
1.20%
Cap:
|
Volume (24h):